Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (8551)	1/30/1999 2:17:00 PM
From: sol dude	Read Replies (1) \| Respond to of 17367

Guys I do not post very much do to work conflicts. (Bond trader For a wire house), But keep in mind that this deal was done by Oppenheimer. Oppy has analyst Matt Geller. This means xoma is on their radar screen. When brokers do deals coverage could be coming. I know for a fact analysts are paid by deal flow (one of the problems of the securities industry). This could potentially big major plus for xoma. Also Lehman advised on Bremuda thing, potential coverage there. I hate dilutions too, but this one may be a blessing in disguise. If the trial is successful it is off to the races. Look at medimune, immunex biogen, Just one man's opinion soldude